On 4.5 million shares InspireMD (NYSE: NSPR) jumps 36.70% to $0.4701 after announcing a pivotal study of CGuard System for carotid artery disease and stroke prevention gets investigational device exemption (IDE) approval. However, before this day NSPR had been plunging from $0.96 to $0.34 although the EPS was getting higher due to expectation beating earnings.
Due to shrinking revenue, InspireMD is getting net loss quarterly as operating expenses are impossible to be decreased. To make medical devices constantly growing salary and wages need to be paid to scientists and engineers to come up with breakthrough technology that is much cheaper and higher quality.
From March to May NSPR could grow significantly to $0.96 only. In June the stock couldn’t recover and kept falling to $0.47. Then the worst days came with a slow plunge in price. The last $0.3410 was a floor that stopped continuous digging below $1.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.